Investigational Drug Information for SAR443820
What is the development status for investigational drug SAR443820?
SAR443820 is an investigational drug.
There have been 6 clinical trials for SAR443820.
The most recent clinical trial was a Phase 1 trial, which was initiated on November 21st 2022.
The most common disease conditions in clinical trials are Motor Neuron Disease, Amyotrophic Lateral Sclerosis, and Sclerosis. The leading clinical trial sponsors are Sanofi and [disabled in preview].
There are two US patents protecting this investigational drug.
Summary for SAR443820
| US Patents | 2 |
| International Patents | 0 |
| US Patent Applications | 12 |
| WIPO Patent Applications | 5 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 1 (2022-11-21) |
| Vendors | 21 |
Recent Clinical Trials for SAR443820
| Title | Sponsor | Phase |
|---|---|---|
| A Study to Evaluate the Effect of SAR443820 on Serum Neurofilament Levels in Male and Female Adult Participants With Multiple Sclerosis | Sanofi | Phase 2 |
| A Study to Assess the Effect of Erythromycin on the Test Medicine (SAR443820) When Given Orally as Tablets to Healthy Adult Male and Female Participants (Part A); and the Effect of Itraconazole on the Test Medicine (SAR443820) When Given Orally as C | Sanofi | Phase 1 |
| Phase 2 Study for SAR443820 in Participants With Amyotrophic Lateral Sclerosis (ALS) | Sanofi | Phase 2 |
Clinical Trial Summary for SAR443820
Top disease conditions for SAR443820
Top clinical trial sponsors for SAR443820
US Patents for SAR443820
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| SAR443820 | ⤷ Start Trial | Kinase inhibitors and uses thereof | Aptuit Verona SRL an Evotec Co , Denali Therapeutics Inc | ⤷ Start Trial |
| SAR443820 | ⤷ Start Trial | Kinase inhibitors and uses thereof | Aptuit Verona SRL an Evotec Co , Denali Therapeutics Inc | ⤷ Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
SAR443820 Development Update and Market Projection
SAR443820, formerly known as DNL788, is an oral, brain-penetrant receptor-interacting serine/threonine-protein kinase 2 (RIPK2) inhibitor developed by Sanofi under its collaboration with Denali Therapeutics. The program was evaluated primarily for amyotrophic lateral sclerosis (ALS). Publicly available clinical information indicates that SAR443820 did not advance toward registration after Phase 2 development, materially reducing its commercial value and the probability of near-term market entry.
What is the development status of SAR443820?
SAR443820 has no publicly established FDA approval, marketing authorization, or active commercial launch. The program’s principal clinical test was the Phase 2 HIMALAYA study in ALS.
| Attribute | SAR443820 |
|---|---|
| Former development code | DNL788 |
| Current code | SAR443820 |
| Developers | Sanofi and Denali Therapeutics |
| Mechanism | CNS-penetrant RIPK2 inhibition |
| Route | Oral |
| Lead indication | Amyotrophic lateral sclerosis |
| Key study | Phase 2 HIMALAYA, NCT05232903 |
| FDA status | No approval identified |
| Commercial status | No marketed product |
| Orange Book status | No listed drug product identified |
| Biosimilar status | Not applicable |
| Generic status | No approved generic pathway identified |
The HIMALAYA trial was designed to assess whether RIPK2 inhibition could reduce neuroinflammatory activity and slow disease progression in patients with ALS. The study used clinical and biomarker endpoints, including measures relevant to neurofilament light chain and functional decline. ClinicalTrials.gov identifies the study as a randomized, placebo-controlled Phase 2 investigation of SAR443820 in ALS patients (U.S. National Library of Medicine, 2022).
Sanofi’s subsequent pipeline decisions indicated that SAR443820 would not proceed as a lead ALS asset. The development setback places the program in a materially different position from earlier Sanofi and Denali projections, which had contemplated a broader role for RIPK2 inhibition in neurodegenerative and inflammatory diseases.
How does SAR443820 work?
RIPK2 is an intracellular kinase involved in signaling downstream of nucleotide-binding oligomerization domain 1 and 2, which detect bacterial peptidoglycan fragments. Abnormal innate immune signaling has been implicated in inflammatory and neurodegenerative disorders.
SAR443820 was designed to inhibit RIPK2 in the central nervous system. The commercial rationale was based on three technical characteristics:
- Oral dosing.
- Brain penetration.
- Modulation of neuroinflammatory signaling rather than direct symptomatic treatment.
This mechanism distinguished SAR443820 from approved ALS drugs such as riluzole and edaravone. Those products have established regulatory and reimbursement positions, while SAR443820 lacked proof of clinical benefit.
What diseases could SAR443820 have treated?
The leading development focus was ALS. RIPK2 inhibition also had theoretical relevance to Parkinson’s disease, multiple sclerosis, inflammatory bowel disease, and other immune-mediated conditions. No public clinical package established an effective dose, a validated biomarker strategy, or a successful expansion plan for those indications.
The failure to demonstrate a sufficiently persuasive ALS profile weakened the rationale for rapid expansion into additional diseases. A new indication would have required fresh dose optimization, safety characterization, and clinical efficacy evidence.
What was the outcome of the Phase 2 HIMALAYA study?
The public development record indicates that HIMALAYA did not produce a result sufficient to support continued ALS development. The program did not progress into a Phase 3 registration trial, and no regulatory submission for SAR443820 has been identified.
The main commercial implications are:
- No demonstrated disease-modifying benefit in ALS.
- No Phase 3 registration program.
- No near-term New Drug Application.
- No identifiable launch date.
- Reduced value of the RIPK2 platform for central nervous system diseases.
- Increased risk that development remains discontinued or inactive.
The program’s failure also affects the interpretation of its biomarker strategy. A CNS-penetrant drug can show target engagement without producing measurable clinical benefit. In ALS, this distinction is important because biomarker movement alone does not establish a disease-modifying effect.
What patents protect SAR443820?
Publicly available materials identify SAR443820 as a Sanofi-Denali development program, but they do not provide a single definitive patent family that can be used to calculate the full composition-of-matter, formulation, method-of-use, and manufacturing estate without a current patent-family review.
| Patent category | Public commercial relevance |
|---|---|
| Composition of matter | Likely primary protection for the small-molecule RIPK2 inhibitor |
| Salt, polymorph, and solid-form claims | Could extend protection beyond the core compound |
| Formulation claims | Potentially relevant to oral CNS delivery |
| Method-of-use claims | Potential coverage for ALS and neuroinflammatory diseases |
| Manufacturing claims | Could create process barriers after composition claims expire |
| Regulatory exclusivity | None identified because no approval is established |
| Orange Book listing | None identified |
| Patent expiration | Cannot be reliably assigned without verified family-level records and terminal-disclaimer analysis |
The strongest expected protection would have been composition-of-matter claims covering SAR443820 or its active chemical series. Method-of-use patents for ALS would have had a shorter practical value because they would not prevent all uses of the compound and could face challenges based on prior-art treatment methods.
Formulation and manufacturing patents would have been secondary barriers. They could have complicated generic development but would not have replaced a weak or expired composition patent. Because the program did not reach commercialization, there is no established Orange Book patent-linkage record and no identified Paragraph IV litigation involving an approved SAR443820 product.
When would SAR443820 lose exclusivity?
SAR443820 has no established market exclusivity date because it has no identified FDA approval. Patent expiration cannot be stated reliably from the development code alone.
If development had continued, potential U.S. exclusivity would have depended on the final approval pathway:
| Exclusivity type | Potential term |
|---|---|
| New chemical entity exclusivity | Five years from FDA approval |
| Orphan-drug exclusivity, if granted | Seven years |
| Pediatric exclusivity | Six additional months |
| Standard U.S. patent term | Generally 20 years from the earliest effective nonprovisional filing date |
| Patent-term adjustment or extension | Potentially available under statutory conditions |
ALS is an orphan-type disease in the United States, so orphan-drug designation and seven-year market exclusivity could have been commercially important. Designation alone, however, would not have created exclusivity without approval.
What is the FDA and Orange Book status of SAR443820?
SAR443820 has no identified FDA-approved label, NDA approval, biologics license application, or Orange Book entry. It is a small molecule rather than a biologic, so biosimilar substitution rules do not apply.
The relevant future regulatory pathways would have been:
- An NDA under the standard 505(b)(1) pathway.
- Orphan-drug designation if the development program met FDA criteria.
- Potential priority review if the product addressed a serious condition and showed substantial improvement over available therapy.
- A confirmatory Phase 3 trial before approval unless FDA accepted an accelerated approval strategy based on a validated surrogate endpoint.
No public evidence establishes that SAR443820 reached any of those filing stages.
Which companies are challenging SAR443820?
No public Paragraph IV challenger, ANDA filer, or patent litigation campaign has been identified for SAR443820. The absence of generic competition reflects development status rather than strong patent protection.
The relevant competitive pressure came from alternative ALS therapies and competing investigational mechanisms:
| Product or approach | Company or sponsor | Status relevant to ALS |
|---|---|---|
| Riluzole | Multiple manufacturers | Approved |
| Edaravone | Mitsubishi Tanabe and generic suppliers | Approved |
| Tofersen | Biogen | Approved for SOD1 mutation-associated ALS |
| Masitinib | AB Science | Investigational |
| Other neuroinflammation programs | Multiple sponsors | Investigational |
SAR443820 would have required differentiation against approved therapies and against investigational agents offering genetic targeting, biomarker-defined treatment, or potentially stronger clinical signals.
What market could SAR443820 have addressed?
The theoretical market was the global ALS treatment market, with possible expansion into other neuroinflammatory diseases. The commercial opportunity was meaningful but constrained by disease prevalence, diagnostic delay, treatment tolerability, and clinical heterogeneity.
A reasonable scenario framework is:
| Scenario | Treated patients | Net annual price | Implied annual revenue |
|---|---|---|---|
| Low | 5,000 | $100,000 | $500 million |
| Base | 15,000 | $150,000 | $2.25 billion |
| High | 30,000 | $200,000 | $6.0 billion |
These figures represent an addressable-product scenario, not a forecast of actual SAR443820 sales. They assume approval, clinical differentiation, reimbursement, and physician adoption. The high scenario would require broad use across diagnosed ALS patients and a durable disease-modifying claim.
A more realistic commercial assessment after the Phase 2 setback is:
- Near-term revenue: zero.
- Probability of a near-term U.S. launch: negligible.
- Probability of material commercial revenue without a new sponsor or new indication: low.
- Residual value: platform know-how, patent rights, and possible out-licensing value.
How strong is the SAR443820 patent and commercial estate?
The commercial estate is weak in practical terms because patent rights do not create value without a viable clinical and regulatory path.
Strengths
- Small-molecule composition claims may provide broad protection if valid and unexpired.
- Oral CNS delivery can support differentiated positioning.
- RIPK2 biology has potential relevance beyond ALS.
- Sanofi and Denali provided substantial development and translational expertise.
Weaknesses
- No approved product.
- No established Orange Book listing.
- No Phase 3 efficacy package.
- No demonstrated advantage over approved ALS treatments.
- No validated expansion indication.
- No commercial manufacturing scale or supply chain.
- Uncertain future ownership and licensing strategy following development curtailment.
The strongest residual asset may be the underlying RIPK2 chemistry rather than SAR443820 as a standalone ALS product.
What licensing deals affect SAR443820?
SAR443820 originated from the Sanofi-Denali collaboration under which Denali contributed its CNS drug-discovery platform and Sanofi obtained rights to selected programs. DNL788 was the Denali development code before the program became associated with Sanofi’s SAR nomenclature.
Publicly reported collaboration materials describe milestone and royalty economics across the alliance, but the precise SAR443820-specific payment obligations, termination rights, patent allocation, and post-termination commercialization rights are not established in the public development record reviewed here. The program’s reduced clinical status lowers the likelihood of near-term milestone realization.
What generic launch risks exist?
There is no current generic launch scenario because SAR443820 is not an approved product. If development restarted and approval occurred, generic risks would depend on:
- Core composition patent expiry.
- Validity of method-of-use claims.
- Availability of a workable non-infringing synthesis.
- Demonstration of bioequivalence for the final oral dosage form.
- Any orphan-drug exclusivity.
- FDA approval of a generic for an unpatented indication.
- Patent-term adjustment and extension.
Manufacturing could create a secondary barrier if the compound required a complex multistep synthesis, difficult chiral resolution, or a protected solid form. Those barriers would not compensate for a failed clinical profile.
How does SAR443820 compare with approved ALS drugs?
| Factor | SAR443820 | Riluzole | Edaravone | Tofersen |
|---|---|---|---|---|
| Status | Clinical development discontinued or inactive | Approved | Approved | Approved for SOD1 mutation-associated ALS |
| Modality | Small-molecule RIPK2 inhibitor | Small molecule | Small molecule | Antisense oligonucleotide |
| CNS targeting | Designed for brain penetration | Systemic, CNS active | Systemic, CNS active | Intrathecal |
| Disease modification | Not established | Limited benefit | Limited benefit | Genotype-specific |
| Biomarker strategy | Neuroinflammation and neurofilament-related measures | None central to label | None central to label | SOD1 and neurofilament measures |
| Generic or follow-on risk | Not currently applicable | Existing generic risk | Emerging generic risk | Biologic-like manufacturing and delivery barriers |
SAR443820’s possible advantage was a disease-modifying neuroinflammatory mechanism with oral administration. Its principal weakness was the absence of clinical validation.
Key Takeaways
- SAR443820, formerly DNL788, is a CNS-penetrant oral RIPK2 inhibitor from Sanofi and Denali Therapeutics.
- Its lead program was Phase 2 HIMALAYA in ALS.
- The program did not advance to Phase 3 or regulatory submission after an unsuccessful clinical development trajectory.
- No FDA approval, Orange Book listing, Paragraph IV challenge, generic launch, or biosimilar pathway has been identified.
- The theoretical ALS market could have supported hundreds of millions to several billion dollars in annual sales under successful approval scenarios.
- Actual near-term SAR443820 revenue is expected to be zero absent a new development program, licensing transaction, or indication restart.
- The residual value lies primarily in the RIPK2 platform, compound patents, and potential non-ALS applications.
FAQs
Is SAR443820 the same drug as DNL788?
Yes. DNL788 was the earlier Denali development code. SAR443820 is the Sanofi development designation associated with the same RIPK2 inhibitor program.
Is SAR443820 approved for ALS?
No. SAR443820 has no identified FDA approval or commercial ALS label.
Did SAR443820 reach Phase 3?
No public evidence shows that SAR443820 entered a Phase 3 registration study. Its principal ALS program was the Phase 2 HIMALAYA trial.
Can patients obtain SAR443820 through a prescription?
No. There is no approved commercial prescription product identified under the SAR443820 or DNL788 names.
Does SAR443820 have value outside ALS?
Potentially. RIPK2 inhibition could be evaluated in other neuroinflammatory or immune-mediated diseases, but no validated clinical efficacy program has established a commercial indication outside ALS.
References
-
Denali Therapeutics Inc. (2022). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. U.S. Securities and Exchange Commission.
-
Sanofi. (2023). Universal registration document and annual financial report. Sanofi.
-
U.S. National Library of Medicine. (2022). Study of SAR443820 in participants with amyotrophic lateral sclerosis: HIMALAYA, NCT05232903. ClinicalTrials.gov.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA.
-
U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations. FDA.
More… ↓
